数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

   ATNM
-- -- --

今开：-- 昨收：-- 最高：-- 最低：--
成交量：--万手 市盈率：-- 总市值($)：-- 换手率：--
加入自选股

首页概览 公司概况 财务分析 高管介绍 股本结构 公司新闻

股本结构

单位：万股
公告日期 2026-08-07 2026-05-08 2026-03-30 2026-03-30 2024-11-14 2024-08-05
证券总股本 3144.14 3137.50 3137.50 3117.59 3119.59 3115.44
普通股本 3144.14 3137.50 3137.50 3117.59 3119.59 3115.44
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2026-06-30 2026-03-31 2026-03-30 2026-03-25 2024-09-30 2024-08-02
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2026-08-07 3144.14 未披露
更多>>
From March 31,2026 to June 30,2026 Stock-based compensation
2026-06-30
2026-05-08 3137.50 未披露
更多>>
From January 1,2026 to March 31,2026 Stock-based compensation
2026-03-31
2026-03-30 3137.50 未披露 定期报告 2026-03-30
2026-03-30 3117.59 未披露 定期报告 2026-03-25
2024-11-14 3119.59 未披露
更多>>
From June 30, 2024 to September 30, 2024 Sale of common stock, net of offering costs Stock-based compensation
2024-09-30
2024-08-05 3115.44 未披露 定期报告 2024-08-02
2024-08-05 3055.06 未披露
更多>>
From March 31, 2024 to June 30, 2024 Sale of common stock, net of offering costs
2024-06-30
2024-04-26 2978.35 未披露 定期报告 2024-04-26
2024-04-26 2939.64 未披露
更多>>
From January 1, 2024 to March 31, 2024 Issuance of common stock from exercise of stock options Sale of common stock, net of offering costs
2024-03-31
2024-03-29 2939.64 未披露 定期报告 2024-03-27
2024-02-02 2776.42 未披露 定期报告 2024-01-30
2024-03-29 2763.42 未披露
更多>>
From December 31, 2022 to December 31, 2023 Issuance of common stock from exercise of stock options Stock-based compensation Sale of common stock, net of offering costs
2023-12-31
2023-11-02 2741.34 未披露
更多>>
From June 30, 2023 to September 30, 2023 Sale of common stock, net of offering costs Stock-based compensation
2023-09-30
2023-08-11 2699.76 未披露 定期报告 2023-08-07
2023-08-14 2698.44 未披露
更多>>
From March 31, 2023 to June 30, 2023 Issuance of common stock from exercise of stock options Sale of common stock, net of offering costs
2023-06-30
2023-05-15 2640.98 未披露 定期报告 2023-05-15
2023-05-15 2572.94 未披露
更多>>
From January 1, 2023 to March 31, 2023 Issuance of common stock from exercise of stock options Sale of common stock, net of offering costs
2023-03-31
2023-03-31 2567.48 未披露
更多>>
From December 31, 2021 to December 31, 2022 Sale of common stock, net of offering costs Stock-based compensation
2022-12-31
2022-11-14 2548.33 未披露 定期报告 2022-11-11
2022-11-14 2521.21 未披露
更多>>
From June 30, 2022 to September 30, 2022 Stock-based compensation Sale of common stock, net of issuance costs
2022-09-30
2022-08-12 2518.47 未披露 定期报告 2022-08-12
2022-08-12 2487.06 未披露
更多>>
From March 31, 2022 to June 30, 2022 Sale of common stock, net of issuance costs
2022-06-30
2022-05-13 2378.45 未披露 定期报告 2022-05-13
2022-03-25 2214.40 未披露
更多>>
From December 31, 2020 to December 31, 2021 Stock-based compensation Sale of common stock, net of costs Issuance of common stock from exercise of stock options
2021-12-31
2021-11-12 2203.08 未披露
更多>>
From June 30, 2021 to September 30, 2021 Stock-based compensation Sale of common stock, net of costs
2021-09-30
2021-10-18 2202.42 未披露 定期报告 2021-09-13
2021-07-30 2133.13 未披露 定期报告 2021-07-28
2021-07-30 2109.09 未披露
更多>>
From March 31, 2021 to June 30, 2021 Stock-based compensation Sale of common stock, net of costs Issuance of shares from exercise of stock options
2021-06-30
2021-05-14 2019.49 未披露 定期报告 2021-05-14
2021-05-14 1924.56 未披露
更多>>
From January 1, 2021 to March 31, 2021 Sale of common stock, net of costs
2021-03-31
2021-03-31 1753.29 未披露
更多>>
from December 31, 2019 to December 31, 2020 Stock-based compensation Sale of common stock and warrants, net of offering costs Issuance of common stock from exercise of pre-funded warrants Issuance of common stock from exercise of warrants
2020-12-31
2020-10-23 1358.65 未披露
更多>>
From June 30,2020 to September 30,2020 Stock-based compensation Issuance of common stock from exercise of warrants and stock options Issuance of common stock from exercise of pre-funded warrants
2020-09-30
2020-10-07 1358.65 未披露 定期报告 2020-09-29
2020-08-14 1358.52 未披露 定期报告 2020-08-13
2020-08-11 1358.53 未披露
更多>>
Upon effectiveness of the reverse stock split, every thirty (30) shares of the Company's pre-reverse split common stock will be combined and reclassified into one (1) share of common stock. The reverse stock split will not modify any rights of the Company's common stock. The reverse stock split will also apply to common stock issuable upon the exercise of the Company's outstanding warrants and stock options, with a proportionate adjustment to the numbers of shares which can be purchased upon the exercise of the warrants and stock options and the exercise prices thereof, and under the Company's equity incentive plan. Immediately after the reverse stock split becomes effective, the Company will have approximately 13,585,268 shares of common stock outstanding (subject to surrender of fractional shares in exchange for cash payment in lieu). No fractional shares will be issued following the reverse stock split.
2020-08-11
2020-08-07 40755.81 未披露 定期报告 2020-08-05
2020-06-29 39515.47 未披露 定期报告 2020-06-29
2020-06-19 41642.40 未披露
更多>>
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or “the Company”) today announced the closing of its previously announced public offering of 76,923,077 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $0.325 per share of common stock (or common stock equivalent). The aggregate gross proceeds from this offering are approximately $25.0 million, before deducting placement agent fees and other estimated offering expenses payable by Actinium.
2020-06-19
2020-06-16 33950.09 未披露 定期报告 2020-06-11
2020-05-08 30334.37 未披露 定期报告 2020-05-07
2020-04-24 35834.37 未披露
更多>>
1.Common Stock Offered by Us 100,833,333 shares of common stock. 2.The number of shares of our common stock that will be outstanding immediately after the offering is based on 175,010,366 shares outstanding as of April 20, 2020.
2020-04-24
2020-04-22 17501.04 未披露 定期报告 2020-04-20
2020-06-29 17483.95 未披露
更多>>
From January 1, 2020 to March 31, 2020 Sale of common stock, net of offering costs
2020-03-31
2019-11-12 16470.12 未披露
更多>>
from June 30, 2019 to September 30, 2019 Stock-based compensation Sale of common stock, net of costs
2019-09-30
2019-08-09 16242.56 未披露 定期报告 2019-08-09
2019-08-09 16203.35 未披露
更多>>
From March 31, 2019 to June 30, 2019 Issuance of common stock from exercise of warrants Sale of common stock and warrants, net of offering costs
2019-06-30
2019-05-10 16203.35 未披露
更多>>
In April 2019, the Company sold 42.9 million shares of common stock at an offering price of $0.385 per share and warrants to purchase up to 42.9 million shares of common stock at an exercise price of $0.50 per share and with a term of 5 years, resulting in gross proceeds of $16.5 million and net proceeds of $15.1 million after deducting underwriting and other offering expenses.
2019-05-09
2019-05-10 11913.60 未披露
更多>>
from January 1, 2019 to March 31, 2019 Stock-based compensation Sale of common stock and warrants, net of offering costs Issuance of common stock from exercise of warrants
2019-03-31
2019-03-15 11913.60 未披露 定期报告 2019-03-15
2019-03-15 11570.30 未披露
更多>>
from December 31, 2017 to December 31, 2018 Stock-based compensation Sale of common stock and warrants, net of offering costs Issuance of commitment shares to Lincoln Park Issuance of common stock from exercise of warrants
2018-12-31
2018-11-09 11569.80 未披露 定期报告 2018-11-09
2018-11-16 11469.80 未披露 定期报告 2018-11-05
2018-11-16 11469.80 未披露 定期报告 2018-10-23
2018-11-09 11046.90 未披露 定期报告 2018-09-30
2018-08-09 11046.35 未披露 定期报告 2018-08-09
2018-08-09 11045.81 未披露 定期报告 2018-06-30
2018-05-10 11031.72 未披露 定期报告 2018-05-10
2018-05-10 11031.67 未披露 定期报告 2018-03-31
2018-03-16 11019.87 未披露 定期报告 2018-03-16
2018-03-16 8007.23 未披露
更多>>
from December 31, 2016 to December 31, 2017 Stock-based compensation Proceeds from the sale of common stock and warrants, net of offering costs Issuance of common stock from exercise of warrants
2017-12-31
2017-11-14 8002.51 未披露 定期报告 2017-11-08
2017-11-03 8002.56 未披露 定期报告 2017-09-30
2017-08-04 8002.06 未披露 定期报告 2017-08-04
2017-08-04 5851.91 未披露 定期报告 2017-06-30
2017-05-15 5844.68 未披露 定期报告 2017-05-15
2017-05-15 5715.24 未披露 定期报告 2017-03-31
2017-03-16 5580.77 未披露 定期报告 2017-03-10
2017-03-16 5580.17 未披露
更多>>
from December 31, 2015 to December 31, 2016 Stock-based compensation Proceeds from the sale of common stock and warrants, net of offering costs Issuance of common stock from exercise of options Issuance of common stock from exercise of warrants
2016-12-31
2016-10-28 5574.71 未披露 定期报告 2016-10-28
2016-10-28 4774.61 未披露 定期报告 2016-09-30
2016-07-29 4771.71 未披露 定期报告 2016-07-28
2016-07-29 4729.32 未披露 定期报告 2016-06-30
2016-05-10 4695.02 未披露 定期报告 2016-05-09
2016-05-10 4492.52 未披露 定期报告 2016-03-31
2016-03-11 4439.11 未披露 定期报告 2016-03-10
2016-03-11 4406.65 未披露
更多>>
From December 31, 2014 to December 31, 2015 Stock-based compensation Proceeds from the sale of common stock and warrants, net of offering costs Issuance of common stock from exercise of options Issuance of common stock from exercise of warrants
2015-12-31
2015-10-30 4201.74 未披露 定期报告 2015-10-29
2015-10-30 4191.74 未披露 定期报告 2015-09-30
2015-08-07 4063.59 未披露 定期报告 2015-08-06
2015-08-07 4048.69 未披露 定期报告 2015-06-30
2015-05-08 3584.59 未披露 定期报告 2015-05-08
2015-05-08 3570.53 未披露 定期报告 2015-03-31
2015-03-16 3548.21 未披露 定期报告 2015-03-16
2015-03-16 2997.18 未披露
更多>>
From December 31,2013 to December 31,2014 Stock-based compensation Proceeds from the sale of common stock, net of offering costs Issuance of common stock from exercise of options Issuance of common stock from exercise of warrants
2014-12-31
2014-10-31 3000.55 未披露 定期报告 2014-10-30
2014-10-31 2961.95 未披露 定期报告 2014-09-30
2014-08-12 2814.71 未披露 定期报告 2014-08-11
2014-08-12 2760.22 未披露 定期报告 2014-06-30
2014-05-12 2556.28 未披露 定期报告 2014-05-09
2014-05-12 2556.23 未披露 定期报告 2014-03-31
2014-06-25 2723.23 未披露 定期报告 2014-03-26
2014-03-24 2532.50 未披露 定期报告 2014-03-13
2014-02-28 2456.54 未披露
更多>>
From December 31,2012 to December 31,2013 Stock-based compensation Proceeds from the issuance of common stock Proceeds from exercise of options Proceeds from exercise of warrants
2013-12-31
From March 31,2026 to June 30,2026 Stock-based compensation
From January 1,2026 to March 31,2026 Stock-based compensation
From June 30, 2024 to September 30, 2024 Sale of common stock, net of offering costs Stock-based compensation
From March 31, 2024 to June 30, 2024 Sale of common stock, net of offering costs
From January 1, 2024 to March 31, 2024 Issuance of common stock from exercise of stock options Sale of common stock, net of offering costs
From December 31, 2022 to December 31, 2023 Issuance of common stock from exercise of stock options Stock-based compensation Sale of common stock, net of offering costs
From June 30, 2023 to September 30, 2023 Sale of common stock, net of offering costs Stock-based compensation
From March 31, 2023 to June 30, 2023 Issuance of common stock from exercise of stock options Sale of common stock, net of offering costs
From January 1, 2023 to March 31, 2023 Issuance of common stock from exercise of stock options Sale of common stock, net of offering costs
From December 31, 2021 to December 31, 2022 Sale of common stock, net of offering costs Stock-based compensation
From June 30, 2022 to September 30, 2022 Stock-based compensation Sale of common stock, net of issuance costs
From March 31, 2022 to June 30, 2022 Sale of common stock, net of issuance costs
From December 31, 2020 to December 31, 2021 Stock-based compensation Sale of common stock, net of costs Issuance of common stock from exercise of stock options
From June 30, 2021 to September 30, 2021 Stock-based compensation Sale of common stock, net of costs
From March 31, 2021 to June 30, 2021 Stock-based compensation Sale of common stock, net of costs Issuance of shares from exercise of stock options
From January 1, 2021 to March 31, 2021 Sale of common stock, net of costs
from December 31, 2019 to December 31, 2020 Stock-based compensation Sale of common stock and warrants, net of offering costs Issuance of common stock from exercise of pre-funded warrants Issuance of common stock from exercise of warrants
From June 30,2020 to September 30,2020 Stock-based compensation Issuance of common stock from exercise of warrants and stock options Issuance of common stock from exercise of pre-funded warrants
Upon effectiveness of the reverse stock split, every thirty (30) shares of the Company's pre-reverse split common stock will be combined and reclassified into one (1) share of common stock. The reverse stock split will not modify any rights of the Company's common stock. The reverse stock split will also apply to common stock issuable upon the exercise of the Company's outstanding warrants and stock options, with a proportionate adjustment to the numbers of shares which can be purchased upon the exercise of the warrants and stock options and the exercise prices thereof, and under the Company's equity incentive plan. Immediately after the reverse stock split becomes effective, the Company will have approximately 13,585,268 shares of common stock outstanding (subject to surrender of fractional shares in exchange for cash payment in lieu). No fractional shares will be issued following the reverse stock split.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or “the Company”) today announced the closing of its previously announced public offering of 76,923,077 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $0.325 per share of common stock (or common stock equivalent). The aggregate gross proceeds from this offering are approximately $25.0 million, before deducting placement agent fees and other estimated offering expenses payable by Actinium.
1.Common Stock Offered by Us 100,833,333 shares of common stock. 2.The number of shares of our common stock that will be outstanding immediately after the offering is based on 175,010,366 shares outstanding as of April 20, 2020.
From January 1, 2020 to March 31, 2020 Sale of common stock, net of offering costs
from June 30, 2019 to September 30, 2019 Stock-based compensation Sale of common stock, net of costs
From March 31, 2019 to June 30, 2019 Issuance of common stock from exercise of warrants Sale of common stock and warrants, net of offering costs
In April 2019, the Company sold 42.9 million shares of common stock at an offering price of $0.385 per share and warrants to purchase up to 42.9 million shares of common stock at an exercise price of $0.50 per share and with a term of 5 years, resulting in gross proceeds of $16.5 million and net proceeds of $15.1 million after deducting underwriting and other offering expenses.
from January 1, 2019 to March 31, 2019 Stock-based compensation Sale of common stock and warrants, net of offering costs Issuance of common stock from exercise of warrants
from December 31, 2017 to December 31, 2018 Stock-based compensation Sale of common stock and warrants, net of offering costs Issuance of commitment shares to Lincoln Park Issuance of common stock from exercise of warrants
from December 31, 2016 to December 31, 2017 Stock-based compensation Proceeds from the sale of common stock and warrants, net of offering costs Issuance of common stock from exercise of warrants
from December 31, 2015 to December 31, 2016 Stock-based compensation Proceeds from the sale of common stock and warrants, net of offering costs Issuance of common stock from exercise of options Issuance of common stock from exercise of warrants
From December 31, 2014 to December 31, 2015 Stock-based compensation Proceeds from the sale of common stock and warrants, net of offering costs Issuance of common stock from exercise of options Issuance of common stock from exercise of warrants
From December 31,2013 to December 31,2014 Stock-based compensation Proceeds from the sale of common stock, net of offering costs Issuance of common stock from exercise of options Issuance of common stock from exercise of warrants
From December 31,2012 to December 31,2013 Stock-based compensation Proceeds from the issuance of common stock Proceeds from exercise of options Proceeds from exercise of warrants